- Change from baseline in mean number of micturitions per 24 hours; time frame: Baseline to end of treatment (12 weeks)<br/>- Number of incontinence episodes reported over 3-day diary; time frame: End of treatment (12 weeks)<br/>- Change from baseline in mean volume voided per micturition; time frame: Baseline to end of treatment (12 weeks)<br/>- Change from baseline in mean number of urgency incontinence episodes per 24 hours; time frame: Baseline to end of treatment (12 weeks)<br/>- Number of urgency incontinence episodes reported over 3-day diary; time frame: End of treatment (12 weeks)<br/>- Change from baseline in mean number of urgency episodes (grade 3 or 4) per 24 hours; time frame: Baseline to end of treatment (12 weeks)<br/>- Change from baseline in mean number of pads per 24 hours; time frame: Baseline to end of treatment (12 weeks)<br/>- Number of pads reported over 3-day diary; time frame: End of treatment (12 weeks)<br/>- Change from baseline in mean number of nocturia Episodes reported in 3-day diary; time frame: Baseline to end of treatment (12 weeks)<br/>- Number of nocturia episodes reported over 3-day diary; time frame: End of treatment (12 weeks)<br/>- Proportion of subjects with at least a 50% decrease from Baseline in mean number of incontinence episodes per 24 hours; time frame: Baseline to end of treatment (12 weeks)<br/>- Proportion of subjects with zero incontinence episodes per 24 hrs at End of Treatment; time frame: End of treatment (12 weeks)<br/>- Proportion of subjects with a mean of less than 8 micturitions per 24 hours at End of Treatment; time frame: End of treatment (12 weeks)<br/>- Change from baseline in total Euroqol European Quality of Life-5 Dimensions (EQ-5D) score (and subscale scores); time frame: Baseline to end of treatment (12 weeks)<br/>- Change from baseline in total OAB-q score (and subscale scores); time frame: Baseline to end of treatment (12 weeks)<br/>- Proportion of responders with at least a 10-point improvement from Baseline in OAB-q subscales; time frame: Baseline to end of treatment (12 weeks)<br/>- Change from baseline in Treatment Satisfaction - Visual Analogue Scale (TS-VAS) score; time frame: Baseline to end of treatment (12 weeks)<br/>- Change from baseline in Patient Perception Bladder Control (PPBC) score; time frame: Baseline to end of treatment (12 weeks)<br/>- Proportion of subjects with at least a 1-point improvement from baseline in PPBC; time frame: End of treatment (12 weeks)<br/>- Proportion of subjects with major (at least 2-point) improvement from baseline in PPBC; time frame: End of treatment (12 weeks)<br/>- Patient and Clinician Global Impression of Change Scales (PGIC and CGIC); time frame: End of treatment (12 weeks)<br/>